BIRC5 and HIV infectious disease: To further assess whether BIRC5 activity in genital T cells is targetable, we used CyTOF to analyze the effect of YM155, a clinically-tested pharmacological inhibitor of BIRC5 (Clemens et al., 2015), on HIV infection of ETs from 3 new donors (Supplementary file 1).